Rhee, J. J., Han, J., Montez‐Rath, M. E., Kim, S. H., Cullen, M. R., Stafford, R. S., . . . Chertow, G. M. (2022). Cardiovascular outcomes associated with prescription of sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with diabetes and chronic kidney disease. Diabetes, obesity & metabolism, 24(5), 928-937.

Rhee, Jinnie J., Jialin Han, Maria E. Montez‐Rath, Sun H. Kim, Mark R. Cullen, Randall S. Stafford, Wolfgang C. Winkelmayer, and Glenn M. Chertow. "Cardiovascular Outcomes Associated with Prescription of Sodium‐glucose Co‐transporter‐2 Inhibitors Versus Dipeptidyl Peptidase‐4 Inhibitors in Patients with Diabetes and Chronic Kidney Disease." Diabetes, Obesity & Metabolism 24, no. 5 (2022): 928-937.

Rhee, Jinnie J., et al. "Cardiovascular Outcomes Associated with Prescription of Sodium‐glucose Co‐transporter‐2 Inhibitors Versus Dipeptidyl Peptidase‐4 Inhibitors in Patients with Diabetes and Chronic Kidney Disease." Diabetes, Obesity & Metabolism, vol. 24, no. 5, 2022, pp. 928-937.